Transforming growth factor-,f (TGF-,f), a regulator of cell growth and differentiation, is secreted by most cultured cells in latent form (L-TGF-fl). Activation of L-TGF-,8 can be achieved by various physico-chemical treatments, including acidification, alkalinization, heating and chaotropic agents. Proposed physiological activators include proteinases and glycosidases, which, however, only lead to limited activation (15-20 % of the total TGF-,8 activity after acidic activation).
INTRODUCTION
Transforming growth factor-,f 6 ) is a pleiotropic factor with important functions in regulation of cell growth, differentiation and development (for reviews see [1, 2] ). The majority of cultured cells studied to date have been shown to secrete TGF-, in an inactive latent form (L-TGF-fl) that does not interact with specific TGF-,/ cell-surface receptors and is not recognized by antibodies to TGF-,/. Three distinct glycosylated receptors for TGF-, have been identified [3, 4] . The presence of specific TGF-,6 receptors on most cell types [5] and the ubiquity of the TGF-fl molecule itself suggest that activation of L-TGFmust be an integral component in the sequence of events leading to growth regulation by TGF-fl.
Several different forms of L-TGF-, have been identified [6] . Platelet-derived L-TGF-/Jl, a large latent complex ( -235 kDa), is composed of three different subunits: the mature TGF-,81 ( 25 kDa dimer) is non-covalently associated with the remainder of the processed precursor (75 kDa dimer), which in turn is disulphide-bonded to a novel 125-160 kDa TGF-,ll-binding protein (TGF-/J1-BP) with epidermal-growth-factor (EGF)-like repeats [7] [8] [9] [10] . Although mature TGF-fll does not contain carbohydrate, TGF-/?l-BP is glycosylated [7] , and the precursor remnant has three potential N-glycosylation sites, all of which carry carbohydrate [7] .
TGF-ft is present in serum complexed with the proteinase inhibitor c2-macroglobulin [11, 12] , which at least in some systems inactivates TGF-, by unknown mechanisms [13] [14] [15] . This complex is distinguished from the other latent forms in that it contains only mature, fully processed, TGF-fl. It has been proposed that oe2-macroglobulin in serum might function as a scavenging molecule for excess TGF-fl [11, 12] .
Recombinant TGF-,81 and TGF-pl2 expressed in mammalian cells were found to be synthesized in latent form [16] [17] [18] . L-TGF-,fl obtained from recombinant sources is a small latent complex, composed of only mature TGF-#ll and the N-terminal remnant of the TGF-,f1 precursor, the latency-associated peptide (LAP) [6, 16, 19] . Site-directed mutagenesis of cysteine residues in the LAP has revealed that dimerization of the precursor pro-region may be crucial for latency [20] . Post-translational modifications of recombinant TGF-,/1 that take place before secretion include processing by acidic proteinases [21, 22] , glycosylation [21, 23] and mannose 6-phosphorylation of the TGF-,81 precursor [23, 24] , as well as disulphide isomerization. In addition, both recombinant TGF-fll precursor and L-TGF-fll isolated from platelets have been reported to bind to the insulin-like growth factor (IGF)-II/mannose 6-phosphate receptor, which has been implicated in the targeting of lysosomal enzymes to the lysosomes [25] . However, all these processing events are clearly distinct from activation events that are required for the generation of biologically active 8 [7, 26, 27] . Several potential physiological mechanisms for activation of the latent form have been investigated. The idea that acidic cellular environments, particularly in tumour tissues, could be conducive to activation of L-TGF-,/ has been proposed recently [28] . Furthermore, the broad-spectrum serine proteinases plasmin and cathepsin D have been proposed to be candidates for physiological activators of L-TGF-,B from human platelets [29] , in fibroblast-conditioned medium [30] or of recombinant L-TGF-,f [29] . However, other reports clearly deny such a physiological role for plasmin [31, 32] . The N-linked glycosylation of TGF-fll-BP has been demonstrated to play a critical role in latency of platelet-derived TGF-,81 [32] . Thus treatment of L-TGF-,fl with endoglycosidase F or sialidase, or addition of sialic acid or mannose 6-phosphate, results in dose-dependent activation.
The activation of L-TGF-fl by cultured cells has been reported in several cases. Monocytes activated by treatment with lipopolysaccharide and neutrophils appear to secrete TGF-,f in a Abbreviations used: Arg-C, endoproteinase Arg-C; EGF, epidermal growth factor; IGF, insulin-like growth factor; IL-2, interleukin-2; LAP, latency-associated peptide; Ova-7 T cells, ovalbumin-specific mouse T helper cells; PBS, phosphate-buffered saline; TGF-,f, transforming growth factor-fl; L-TGF-,8, latent TGF-fl; rhTGF-/J, recombinant human TGF-,f; TGF-,l1-BP, TGF-fll-binding protein.
fully active form, since acidification of the conditioned medium does not increase the amount of TGF-/6 activity [33] . A human erythroleukaemia cell line (HEL) is capable of activating added recombinant L-TGF-/1l in a cell-associated manner [34] . When osteoclasts are activated by incubation with vitamin A or with 'bone particles, they liberate active TGF-,/ from the latent complex produced by bone organ cultures [35] . However, no factor or enzyme responsible for the activation of L-TGF-fl could be demonstrated in conditioned medium from activated osteoclasts [35] . Finally, the production of an activated form of TGF-,8 by co-cultures of endothelial cells and pericytes or smooth-muscle cells [36, 37] has been reported. The activation appears to be partially mediated by plasmin and requires close contact between the two cell types [38] .
As much ambiguity about the susceptibility of latent forms of TGF-, to activation by a single enzyme remains, we have undertaken this study to measure effects of different enzymes on activation of platelet-derived L-TGF-/Jl. However, there was no evidence for activation of L-TGF-fll from human platelets by plasmin and a number of other proteinases or neuraminidase. Consequently, the elucidation of physiological activation mechanisms may be derived from studies of cultured cells with the ability to secrete active TGF-fl or to activate L-TGF-/J from other sources. Indeed, when investigating human glioblastoma cells which secrete bioactive TGF-,82 [39] , it was found that these cells release factor(s) able to activate L-TGF-fll from human platelets.
MATERIALS AND METHODS

Materials
The polyclonal neutralizing antibody specific for TGF-,81 was purchased from Oncomembrane Inc. (ams biotechnology, Lugano, Switzerland). The purified anti-TGF-,82 IgG [39] was generously given by Sandoz Co., Basel, Switzerland. The nonimmune rabbit control IgG was from Endogen Inc. (Boston, MA, U.S.A.). Highly purified recombinant human (rh) TGF-fll and -,f2 were kindly provided by Genentech Inc. (San Francisco, CA, U.S.A.) [40] and Sandoz Co. respectively. Clinically outdated platelet concentrates were obtained through the courtesy of the Swiss Red Cross (Zurich, Switzerland). All other chemicals used were of reagent grade and purchased from common commercial sources.
Methods
Cell culture media. Cells were cultured in an incubator in a humidified atmosphere containing 7 % CO2 at 37 'C. The following cell-culture media were used. (a) Ova-7 medium: Iscove's medium (Gibco, Paisley, Scotland, U.K.), supplemented with 1 mM-L-glutamine (Gibco), soybean phosphatidylcholine (50 mg/l; Nattermann Phospholipid G.m.b.H., Koln, Germany), human transferrin (100 mg/ml; Behringwerke A.G., Marburg, Germany), BSA (1 g/l; Fluka A.G., Buchs, Switzerland) and 2-mercaptoethanol (50 Glioblastoma cells and production of supernatant. The human glioblastoma cell line 308 used in this study has been described [41] . For solution which has proved to be incompatible in the Ova-7 T cell proliferation assay. Therefore, the enzyme was transferred to phosphate-buffered saline (PBS; 140 mM-NaCl/10 mMNa2HPO4/3 mM-KH2PO4) by using a Centricon 10 micro-con- A.G. Before use, all proteinases were tested for proteolytic activity in a spectrophotometric assay as explained below. For partial proteolytic digestion, samples were incubated with the indicated concentrations of enzymes. The incubations were performed at 37°C for 2 h in PBS (pH 8.5). Proteinase activity was then quenched by addition of Ova-7 culture medium, which contains 0.1 % BSA, and samples were subjected to assessment of growth-inhibitory activity either directly or after acidification.
Treatment with neuraminidase. Samples were incubated with the indicated concentrations of neuraminidase type V (EC 3.2.1.18) from Sigma (product no. N 2876) at 37°C for 18 h in PBS (pH 6.0). Subsequently they were diluted with Ova-7 culture medium, and growth-inhibitory activity was determined either directly or after acidification.
Partial purification of latent TGF-pI1 from human platelets.
Standard platelet concentrates were processed as described previously [27] . Briefly, platelets were washed with PBS, added to Growth-inhibitory activity was determined either directly (Fl)-or after incubation with specific neutralizing antibodies directed against TGF-/Jl (1) (80 ,ug/ml) and TGF-fl2 (~1) (80 ,ug/ml), or with non-immune rabbit control IgG (1) (80 Isg/ml. In order to show the high specificity of the antibodies used, rhTGF-flI (10 pM) and rhTGF-/?2 (10 pM) were subjected to the same treatment. Results are expressed as described above. containing most of the L-TGF-,81 were pooled, and this pool will be referred to below as partially purified L-TGF-,fl.
Preparation of neutral and acidified samples. Before acidification, samples were diluted with Ova-7 culture medium (containing 0.1 % BSA). Then and hydrolysis of the substrate was monitored by an increase in A405 N-Benzoyltyrosine p-nitroanilide (Bachem A.G.) was used as substrate for chymotrypsin [43] , and hydrolysis of the substrate was monitored by an increase in A385' N-Succinyl-L-alanyl-Lalanyl-L-alanine p-nitroanilide (Bachem A.G.) was used as substrate for elastase [44] , and hydrolysis of the substrate was monitored by an increase in A405. RESULTS Our previous observation that glioblastoma cells secrete biologically active TGF-,82 [39] Although limited action of proteinases and glycosidases has been reported to result in the partial activation of native L-TGF-/?1 [30, 32] , controversy about this point has arisen recently. Samples were incubated either without (0) or with (El) neuraminidase (2 units/ml) for 18 h at 37 'C. Growth-inhibitory activity at various final concentrations is shown for rhTGF-,l8 (a) and rhTGF-fl2 (b) . Results are expressed as described in Fig. 1 Fig. 1 .
Therefore, human platelet-derived L-TGF-flI was tested for susceptibility to such action. As shown in Fig. 2 , partial proteolytic digestion of L-TGF-fll with plasmin (Sigma) does not liberate active TGF-,/1 from its latent complex, but even somewhat decreases activity of L-TGF-,81 (Fig. 2a) as well as rhTGFfl1 (Fig. 2b) . Comparable results are obtained when using crude glioblastoma supernatant as a source of TGF-/?2 ( Fig. 2c) or rhTGF-fl2 (Fig. 2d) . Pretreatment of platelet-derived L-TGF-fll with plasmin does not affect subsequent activation of L-TGF-/ll by transient acidification (Fig. 2a) . The same series of experiments, when performed with plasmin purchased from Boehringer Mannheim and used at a concentration of up to 6 units/ml, revealed similar results (not shown).
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Several other serine proteinases were used in a further series of experiments. Similarly to plasmin, the endoproteinase Arg-C hydrolyses peptide and ester bonds at the carboxylic side of arginine residues in a highly specific manner. Chymotrypsin and elastase were chosen for their specificity for cleavage at the carboxylic side of aromatic and uncharged non-aromatic amino acids respectively. All TGF-,/1-BP are crucial to its latency [32] . As illustrated in Fig.  3 , no activating effect was observed when platelet L-TGF-,/l or glioblastoma supernatant was incubated with neuraminidase (2 units/ml). Control incubations of rhTGF-,/l and rhTGF-/?2 with neuraminidase led to the surprising finding that neuraminidase markedly increased the growth-inhibitory activity of rhTGF-,/l (Fig. 4a) , whereas no such effect could be detected with rhTGF-fl2 (Fig. 4b) . Latent TGF-,81 was incubated with an equal volume of glioblastoma supematant for-6 h at 37°C in the presence of BSA (0.5 mg/ml). Neutral (Cl) or acidified (-) samples were then incubated with a neutralizing antibody specific for TGF-p12 at a concentration of 40 ,ug/ml, and growthinhibitory activity was subsequently determined by titration on Ova-7 T cells. Alternatively, L-TGF-fll was incubated with medium used for the production of glioblastoma supernatant and further processed exactly as described above (0, 0). Efficient neutralization of TGF-,/2 present in glioblastoma supernatant was ensured by incubating it with an equal volume of PBS and further processing as above (A, A). Results are expressed as described in Fig. 1 .
1991
incubations somewhat vanished, possibly owing to non-specific absorption. When supernatants from control wells with glioblastoma cells alone were analysed for their content of TGF-,f2 in a parallel experiment, it was recognized that the glioblastoma cells secreted increasing amounts of TGF-/J2 in the course of the incubation (results not shown). Therefore, as expected, the active TGF-fl2 present in acidified supernatant from glioblastoma cells after 48 h could not be completely neutralized when assayed at a final dilution of 1:1600, owing to the exhausted capacity of the anti-TGF-fl2 antibody.
In a further series of experiments, cell extracts prepared by sonication of glioblastoma cells were incubated for up to 4 h with L-TGF-/3l, and TGF-fll activity was subsequently measured in the Ova-7 T cell proliferation assay. As seen in Table 2 , a crude extract as well as an extract devoid of membrane particles were tested and found to exert no stimulatory effect on the growthinhibiting activity of platelet L-TGF-fll.
In further experiments, cell-free glioblastoma supernatant was tested for its activating capacity for human platelet-derived L-TGF-/3l. The results of a representative experiment are illustrated in Fig. 6 . It is important to note that the TGF-,82 activity derived from the glioblastoma cells themselves was completely and specifically neutralized before determination of platelet-derived TGF-/J1 activity in the Ova-7 assay. Incubation of platelet L-TGF-fll with a glioblastoma-cell-derived supernatant results in an almost 3-fold increase in native platelet-derived TGF-/31 activity by 6 
DISCUSSION
Cultured human glioblastoma cells have been shown to secrete an immunosuppressive factor which inhibits the lectin-induced response of mouse thymocytes [45] , the generation of cytotoxic T cells [40, 45] , as well as the IL-2-induced growth of IL-2-dependent T-cell lines [13, 45] . This factor, initially termed glioblastomaderived T-cell suppressor factor ('G-TsF'), has been purified and cloned from a human glioblastoma cell line and was found to be TGF-fl2 [46] [47] [48] . Most interestingly, further investigations have revealed that cultured human glioblastoma cells preferentially produce a biologically active form of TGF-,82 [39] . In Lymphocytes have receptors for active TGF-fl, and active TGF-# prevents IL-2-driven proliferation of T cells [13, 49] . As shown herein, active TGF-/3 suppresses the growth of an ovalbumin-specific mouse T helper-cell clone. We have confirmed previous reports [26, 27] that transient acidification activates partially purified L-TGF-/31 from human platelets by a factor of 10-20-fold. Moreover, native L-TGF-/31 also has intrinsic growth-inhibiting activity in this assay system. This finding is analogous to some other reports, since native L-TGF-fl purified to homogeneity from human platelets was recently reported to inhibit cell growth when added at high concentrations, but to increase activity 200-fold after transient exposure to 1 M-HCI when tested on pig aortic endothelial cells [32] . In [50] . Limited activation of L-TGF-fl from chick-embryo fibroblasts [26] and from fibroblast-conditioned medium [30] at pH 4-5 has been reported previously. However, in our experiments, and according to two other reports [7, 31] [32] , it has been reported that incubation of platelet L-TGF-fll and fibroblast L-TGF-,ll with increasing amounts of plasmin produced an increase in TGF-fJ competing activity [29, 30] . In addition, four distinguishable forms of bone-matrixderived L-TGF-,l were described, only two of which are activated up to 300% by plasmin [51] . A mechanism for the activation of recombinant L-TGF-,ll by plasmin [29] [31] . The results of the present work further support the evidence that plasmin is unlikely to represent the physiological mechanism by which cells activate L-TGF-fl in vivo, especially in the light of the fact that levels of plasmin that liberate some active TGF-,3 also cause substantial degradation thereof.
To investigate the possibility that sialic acid residues present in the latent complex of TGF-flI may be involved in complex formation and thus important for latency, we tested neuraminidase/sialidase, which specifically removes sialic acid residues L52], for activating effects on L-TGF-/1i. Neuraminidase/ sialidase up to a concentration of 2 units/ml had no relevant effect on the growth-inhibiting activity of human platelet L-TGF-fli. It has been reported that treatment with a low concentration of neuraminidase/sialidase (1 unit/ml) activates platelet L-TGF-/Ji significantly only if the treated L-TGF-,f1
was added at high concentration to the target cells [32] . The activating effect of neuraminidase/sialidase on recombinant L-TGF-/Ji is also reported to be limited [31] . The increase in activity of highly purified rhTGF-/ll after treatment with neuraminidase/sialidase as reported here (Fig. 4) In addition, activated osteoclasts can activate the bone-derived L-TGF-, complex, probably by the local acidic environment produced by them [35] .
Conversion of L-TGF-fl into biologically active TGF-,8 was also reported in co-cultures of endothelial cells and pericytes or smooth-muscle cells [36, 37] . Activation appeared to require cell-cell contact or the very close apposition of the two different cell types. The activation reaction also seemed to require plasmin, as inclusion of inhibitors of plasmin in the heterotypic culture medium abrogated the formation of active TGF-,f [36] . In addition, it has been described that the generation of TGF-f in these co-cultures stimulated the production of the proteinase inhibitor plasminogen activator inhibitor-I (PAI-1) [38] . The increased expression of PAI-I subsequently blocked the activation of the proteinase required for conversion of L-TGF-, into TGF-,f. Thus the activation of L-TGF-,/ in this kind of cell co-culture appears to be a self-regulating system. Recently, mixed lymphoid cell cultures have been shown to produce endogenously L-TGF-,f capable of regulating lymphocyte activities in vitro [53] . The mechanism by which these cells convert L-TGF-,f into its apparently active form remains unclear.
As indicated by the lack of activation by incubation of platelet L-TGF-,f1 with cellular extracts prepared from glioblastoma cells, activation of L-TGF-,81 is not attributable to a process which is localized intracellularly. It must be considered, however, that we cannot exclude the destruction of a putative activating mechanism in the course of preparation of cell extracts. Specifically, the spatial orientation of enzymes may be critical for activation, and sonication is a relatively harsh treatment probably incompatible with preservation of enzyme activity.
The cellular mechanism by which glioblastoma cells produce TGF-p32 in biologically active form still awaits elucidation.
However, as shown in the present report, glioblastoma cells secrete factor(s) which are also able to activate platelet-derived L-TGF-/J1. Therefore the mechanism of activation of latent forms of TGF-f probably is similar for both TGF-/li and TGFf2. The similarity in the properties of the latent complexes of the different TGF-/Jo subtypes has been established as far as structure and activation are concerned [31] . It remains to be clarified whether the activation of latent forms of TGF-, is mediated by a multi-step process or a single entity. Interestingly, pretreatment of platelet L-TGF-fll with glioblastoma supernatant and subsequent activation by transient acidification leads to a more pronounced increase of TGF-,8 activity than does control acidification alone. In this regard, it is important to note that activation in vitro of recombinant L-TGF-/ll as well as of platelet L-TGF-fll by transient acidification is at least partially reversible, in a time-and concentration-dependent manner [6, 8] . In addition, the rate of re-association of the latent complex was reported to be dependent on sample preparation and mode of activation [31] .
Consequently 
